Date |
|
May 1, 2014 |
CEL-SCI Reports April 2014 is Another Record Month for Patient Enrollment in Its Phase III Head and Neck Cancer Trial |
Apr 29, 2014 |
CEL-SCI Corporation Receives $3 Million from Warrant Exercises |
Apr 28, 2014 |
Southern Illinois University School of Medicine Becomes Clinical Site for CEL-SCI’s Global Phase III Immunotherapy Head and Neck Cancer Trial |
Apr 22, 2014 |
CEL-SCI to Sponsor Symposium on Multikine at European Congress on Head & Neck Oncology 2014 |
Apr 17, 2014 |
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $10 Million |
Apr 14, 2014 |
CEL-SCI Corporation Prices $10 Million Public Offering of Common Stock and Six Month Warrants |
Apr 8, 2014 |
Henry Ford Health System of Detroit to Enroll and Treat Patients in CEL-SCI’s Phase III Head and Neck Cancer Clinical Trial |
Apr 2, 2014 |
Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI’s Global Phase III Head and Neck Cancer Trial |
Apr 1, 2014 |
CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial |
Mar 27, 2014 |
CEL-SCI Corporation (CVM): Significant Potential, but a Long Way from Results |